|Targets||c-Kit | FGFR | FLT3 | PDGFR | VEGFR|
|Description||SU11652 is a cell-permeable and sunitinib-like inhibitor of tyrosine kinase receptor (RTK) and angiogenesis with antineoplastic property. It selectively inhibits PDGFR-β, VEGFR2, FGFR1, FLT3 (IC50 values of 3, 27, 170 and 1.5 nM, respectively) and Kit family members (IC50=~10-500 nM).|
|Brife Description||RTK inhibitor|
|Melting Point||>210°C (dec.)|
NSC12 is an extracellular trap for fibroblast growth factor 2 (FGF2). It binds FGF2 with Kd value of 51 µM and interferes with its interaction with FGFR1 withou...
SU4984 is a FLT3 inhibitor that induces growth arrest, apoptosis, and cell cycle arrest in Ba/F3 and AML cell lines expressing a constitutively activated FLT3. ...
TG 100801 is the prodrug of TG 100572, which is a multi-targeted kinase inhibitor that inhibit select growth factor receptor tyrosine kinases and Src familt kin...
BIBF 1120 esylate
Nintedanib esylate is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β.
CHMFL-FLT3-122 is a potent and selective FLT3 inhibitor (IC50 = 40 nM) with >10-fold and 170-fold selectivity for FLT3 over BTK kinase and c-KIT kinase. It caus...
axitinib is an orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platel...
Anlotinib Dihydrochloride is a novel multi-target tyrosine kinase inhibitor with potential antineoplastic and anti-angiogenic activities, which was designed to ...
LY2874455 exhibits a potent activity against FGF/FGFR-mediated signaling in several cancer cell lines and shows an excellent broad spectrum of antitumor activit...
Brivanib is the hydrolyzed form of Brivanib alaninate, which is a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic...
PD173074 is a small-molecule FGFR3-selective tyrosine kinase inhibitor (TKI), as a therapeutic modality using eight UC cell lines. PD173074 suppressed cell prol...
Cabozantinib is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 1...
Crenolanib is an orally bioavailable small molecule, targeting the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Cren...
Imatinib (INN), marketed by Novartis as Gleevec (Canada, South Africa and the USA) or Glivec (Australia, Europe and Latin America), and sometimes referred to by...
Masitinib mesylate is a novel inhibitor for Kit and PDGFRα/β with IC50 of 200 nM and 540 nM/800 nM, weak inhibition to ABL and c-Fms.
SU14813 is an oral, multitargeted tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor...
SU11652 is a cell-permeable and sunitinib-like inhibitor of tyrosine kinase receptor (RTK) and angiogenesis with antineoplastic property. It selectively inhibit...
BPR1J-097 is a novel potent FLT3 inhibitor with an IC50 of 11 nM.
Tandutinib, also known as MLN 518, is a piperazinyl quinazoline receptor tyrosine kinase inhibitor with antineoplastic activity. Tandutinib inhibits the autopho...
DMPQ dihydrochloride is a potent and selective inhibitor of human vascular β-type platelet derived growth factor receptor tyrosine kinase (PDGFRβ) (IC50 = 80 nM...